- Key Release /Ad hoc announcement pursuant to Art. 53 LR CANOPY-1 Phase III study did not meet its primary endpoints of overall survival (OS) and progression-free survival (PFS)…
- Media Release /
Novartis announces FDA and EMA filing acceptances of Beovu® for patients with diabetic macular edema
Regulatory decisions for Beovu (brolucizumab) in diabetic macular edema (DME) are expected in mid-2022 in the US and Europe DME is the leading cause of blindness in adults in developed… - Story /
Advanced Accelerator Applications is working on marrying targeted drug design with nuclear medicine technology to develop drugs that can recognize and treat diseases.
- Story /
At Novartis, we celebrate life and recognize moments that matter. Michael Wieser shares his experience of parental leave and becoming a father of two.
- Story /
A strong background in biological research prepared Daniel Rooks for his role in shaping the early clinical development of new medicines
- Story /
After 40 years of working in information technology, Jim Barrington took a partial retirement from his job as Novartis’ chief information officer and started looking for new ways to apply his skills.
- Story /
Cynthia lives with Heart Failure with preserved Ejection Fraction, a complex and challenging condition.
- Story /
Lake Victoria in southwestern Kenya is on the front line in the fight against malaria, and Agnes Akoth is a key figure.
- Story /
Receiving a breast cancer diagnosis is difficult, but these young women faced an especially challenging diagnosis: stage IV metastatic breast cancer.
- Story /
Ahead of World Malaria Day, Novartis and Malaria No More delivered 2 million pediatric antimalarials to Zambia provided through the Power of One campaign.
Pagination
- ‹ Previous page
- 1
- …
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- …
- 277
- › Next page